1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.142-142(
- Contribution to journal › Published meeting abstract
-
Mark
Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma
(
- Contribution to journal › Article
- 2005
-
Mark
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis
(
- Contribution to journal › Article
- 2003
-
Mark
Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB
(
- Contribution to journal › Article
-
Mark
Mutated V-H genes and preferential V(H)3-21 use define new subsets of mantle cell lymphoma
(
- Contribution to journal › Article
- 2002
-
Mark
Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy
(
- Contribution to journal › Article
-
Mark
A population-based study of the outcome for patients with first relapse of Hodgkin's lymphoma
(
- Contribution to journal › Article